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Abstract
Background: The concept of benefit sharing to enhance the social value of global health research in resource
poor settings is now a key strategy for addressing moral issues of relevance to individuals, communities and host
countries in resource poor settings when they participate in international collaborative health research.
The influence of benefit sharing framework on the conduct of collaborative health research is for instance
evidenced by the number of publications and research ethics guidelines that require prior engagement between
stakeholders to determine the social value of research to the host communities. While such efforts as the
production of international guidance on how to promote the social value of research through such strategies as
benefit sharing have been made, the extent to which these ideas and guidelines have been absorbed by those
engaged in global health research especially in resource poor settings remains unclear. We examine this awareness
among stakeholders involved in health related research in Kenya.
Methods: We conducted in-depth interviews with key informants drawn from within the broader health research
system in Kenya including researchers from the mainstream health research institutions, networks and universities,
teaching hospitals, policy makers, institutional review boards, civil society organisations and community
representative groups.
Results: Our study suggests that although people have a sense of justice and the moral aspects of research, this
was not articulated in terms used in the literature and the guidelines on the ethics of global health research.
Conclusion: This study demonstrates that while in theory several efforts can be made to address the moral issues
of concern to research participants and their communities in resource poor settings, quick fixes such as benefit
sharing are not going to be straightforward. We suggest a need to pay closer attention to the processes through
which ethical principles are enacted in practice and distil lessons on how best to involve individuals and
communities in promoting ethical conduct of global health research in resource poor settings.
Background
The concept of benefit sharing in health related
research, which at a minimum, entails the elucidation of
what if anything, is owed to participants, their commu-
nities and host nations that take part in such research,
has recently emerged as an important strategy for
addressing moral issues of relevance to individuals, com-
munities and host countries in resource poor settings
when they participate in international collaborative
health research [1-3]. This concept requires considera-
tion of a new ethical issue, the social value of
research [4], by involving research participants and the
researched communities in ensuring that global health
research undertaken in resource poor settings is not
exploitative and is responsive to the expressed needs of
such settings. Benefit sharing was developed as a strat-
egy to forestall the potential for exploitation of indivi-
duals, groups and even countries that host research and
provide such groups with reasonable returns, thus pro-
moting the social value of the research [5].
Concerns over the exploitative potential of global
health research arose from the realisation that: i) the
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being undertaken in developing countries had increased,
in itself a positive move, arising from advocacy asso-
ciated with the 10/90 gap [6,7], ii) that advances in
science and technology especially the computing and
statistical capabilities that made Genome Wide Associa-
tion (GWAs) studies possible not only to implicate indi-
viduals, but also whole populations in research [8,9]
and, iii) the understanding that the pathway between
knowledge generation and improved care is not straight
forward [10-12].
The potential of the above developments to produce
unfairness is exacerbated by the fact that most resource
poor settings are also characterised by high unmet
healthcare needs, weak capacity among ethical and other
research regulatory systems to safeguard the interests of
research participants, and an often poor exchange
model capable of translating research findings into
improved health [4,13-15]. The argument has been that
although these conditions are not sufficient for research
to be exploitative, they nonetheless predispose partici-
pants in resource poor settings to exploitation.
The consideration of the social value of research and
the need to engage with benefit- sharing within health
related research as strategies to address the potential for
exploitation have important similarities. The two call for
prior consideration of the moral obligations of research-
ers (and funding institutions) that arise once individuals
and groups participate in health related research, includ-
ing the identification of the benefits to be shared, the
beneficiaries and where the responsibility for providing
the benefits lie. These strategies have influenced the
conduct of collaborative health research as evidenced by
the number of publications and research ethics guide-
lines that require prior engagement between stake-
holders to determine the social value of research to the
host communities [14,16-19]).
While efforts have therefore been made to produce
international guidance on how to promote the social
value of research through such strategies as benefit shar-
ing, the extent to which these ideas and guidelines have
been absorbed by those engaged in global health
research especially in resource poor settings remains
unclear. The work reported here aimed to explore
awareness of the concept of benefit sharing among sta-
keholders involved in health related research in Kenya.
Methods
This study was conducted among stakeholders drawn
from within the broader health research system in
Kenya. Overall, the Kenya Medical Research Institute
(KEMRI) is the main body responsible for health related
research in Kenya through its ten (10) research centres
located in different parts of the country. KEMRI is
mandated to carry out research into human health and
generate evidence to improve health status in Kenya and
globally. The Institute mainly undertakes research in
areas such as infectious diseases; parasitic diseases; epi-
demiology, public health and health systems research;
and biotechnology and non-communicable diseases.
Besides KEMRI, several other bodies actively conduct
health related research in Kenya, key among them, pri-
vate and public hospitals, and universities with Health/
Medical Sciences departments. Hospitals that undertake
health related research include; Kenyatta National Hos-
pital (KNH) in conjunction with the College of Health
Sciences of the University of Nairobi, and Moi Teaching
and Referral Hospital (MTRH) in conjunction with Moi
University. In addition, there are local networks, interna-
tional research institutions, pharmaceutical companies,
charities/foundations and International Non Govern-
mental Organisations (NGOs) that equally conduct
research related to healthcare. The accounts that we
report here were articulated by researchers, members of
Institutional Review Boards (IRBs), policy makers, civil
society organisations, research sponsors and community
representative groups within such institutions or
impacted by their research. We have previously reviewed
the recommendations made by various international and
region specific research ethics guidelines regarding ben-
efit sharing [20] as a framework of theory that might be
expected to guide how the research system acts in real
settings. In the review, we argued that there is less con-
sensuses among research ethics guidelines, regarding the
specific responsibilities of researchers over what is ethi-
cal in promoting the social value of research. We further
noted that this was likely to have practical implications
for efforts aimed at enhancing the social value of global
health research undertaken in resource poor settings.
Selection of key informants and data collection
Key informant and in depth interviews were conducted
with 52 respondents drawn from institutions described
above. Respondents were grouped into 6 categories (see
table 1), representing actors that are expected to conti-
nually engage with ethical issues arising from the con-
duct of health related research. These groups might be
expected to be involved in negotiations relating to the
promotion of the social value of research, and the con-
sideration of research benefits in particular.
We did not pre-specify formally the number of inter-
views that would be conducted. Instead we adopted an
initially selective approach where respondents that were
deemed likely to have engaged with issues relating to
benefit sharing were theoretically sampled as the study
proceeded [21]. Thus the final number of interviews
from the different categories was determined by the
standard principle in qualitative research of data
Lairumbi et al. BMC Medical Ethics 2011, 12:20
http://www.biomedcentral.com/1472-6939/12/20
Page 2 of 9saturation, the point at which no new ideas, views or
experiences were being expressed.
Data collection was undertaken over a six month per-
iod between October 2007 and April 2008. Potential
respondents were contacted by telephone, to discuss the
study objectives and inclusion criteria. After accepting
this preliminary invitation formal participation in the
study was confirmed at the time of interview when each
respondent was asked to provide individual, written
informed consent. Interviews were conducted face-to-
face and conversation recorded together with detailed
notes of the discussion. The interviews were conducted
by the principal investigator (LM), except for those con-
ducted among members of a community representative
groups which were conducted with the help a research
assistant who was more conversant with Kiswahili. The
assistant was trained on how to conduct qualitative
interviews and was accompanied by the principal
researcher during these interviews. Interview guides
were prepared based on literature review, analysis of
research ethics guidelines and initial findings from the
pilot phase.
The purpose of the research was explained as an exer-
cise to understand how the importance of research/
study was communicated to research participants or
framed including why it was important to participate in
research. Respondents were therefore asked to reflect
based on research they were involved in, over what they
considered to be the benefits, the beneficiaries and the
obligation of various actors to provide the benefit. Parti-
cipants who did not have an immediate experience to
draw from were invited to reflect based on two exam-
ples of clinical trials; Malaria and HIV/AIDS clinical
vaccine trials. The interview guides were therefore
framed around stakeholder’s views of the benefits, bene-
ficiaries, obligations and how such decisions were made.
All respondents except community representatives were
however asked whether they had come across the term
“benefit sharing”, as a way of teasing out their level of
engagement with the debate over fairness in global
health research. The interview process was the main
tool for interviews exploring how stakeholders under-
stood the new concept of benefit sharing within global
health research. Initial observations from the pilot,
revealed that respondents were often unfamiliar with the
language and issues relating to benefit- sharing, requir-
ing initial conversations to explore and develop the
topic idea.
The interview encounter was therefore the ultimate
context within which to ensure production of valid
knowledge (the emphasis was not on observation, but
rather, conversation and interaction). This was made
possible by interviewing reliable “witnesses” who were
actively involved in health related research and the use
of valid documents (such as the research ethics guide-
lines) and arguments as part of the social interaction.
Data management and analysis
Audio recorded interviews were transcribed verbatim
and translated where necessary. Analysis was done fol-
lowing a grounded theory approach [22]. Preliminary
analysis entailed progressive coding and categorisation
of issues emerging from the interviews. The transcripts
were read several times in order to identify meaning
units for developing an organising system for coding the
data. We developed our organising system following a
criterion suggested by Srivastava and Hopwood, [23],
which involves exploring data alongside the issues peo-
ple were talking about in the interviews, the initial
objectives of the research and the contradictions
between the two. The analysis proceeded from open
coding, comparing transcripts and coding into each
other to the point of saturation and later organising the
codes into themes.
Ethical Considerations
Ethical approval for this work was granted by the
national ethics review committee in Kenya (NERC).
Informed consent was obtained from all respondents,
including the permission to record the conversation. In
most cases, respondents were happy with the recording,
except for a few who declined. Other ethical considera-
tions were the need to protect the confidentiality of the
respondents, which were potentially revealing because of
the small sample, and the nature of the people inter-
viewed. In this case, all the interviews were anonymised
by assigning pseudonyms and any attribution was made
to the category from which the respondents were
Table 1 Categories of participants and number of interviews under each
Participating institutions Number of Interviews
Research institutes & University depts. with health science departments/schools/institutes 16
NGOs with research functions 3
Policy makers 4
Ethical review bodies & Research coordinating bodies 11
Pharmaceutical Firms & Other funding bodies 7
Civil Society Organisations (CSOs) &KEMRI community representative/Advisory groups 11
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representation and interpretation were considered, and
every attempt was made to stay close to the data with-
out distorting the salient differences between and
among the categories of respondents.
Results
We present below, the stakeholders’ awareness of
debates within academic and regulatory literature relat-
ing to benefit sharing, as well as the moral issues that
are seen to arise from the conduct of collaborative
health related research in resource poor settings. We
later examine the extent to which these views have any-
thing in common with those being discussed in the
bioethics and regulatory literature about benefit sharing
while pointing to some of the implications for this
understanding.
Awareness of debates relating to benefit-sharing
In most cases interviews started with questions meant to
explore interviewees’ awareness of academic and regula-
tory debate about the fair sharing of benefits in interna-
tional research undertaken in developing countries.
Stakeholders were asked whether they had come across
the term benefit sharing in the context of research
ethics, primarily, to tease out their familiarity with the
debates leading to the emergence of the need to pro-
mote the social value and benefit sharing as ethical
imperatives. In this particular instance the term ‘social
value’ is used in a broad sense to include all the ques-
tions about the value/benefits of the research to com-
munities including its relevance to their health care
needs. Seen from this perspective, benefit sharing is one
possible way of making research to have social value.
At the research level: Awareness among researchers
“...Benefit sharing? No, I know the English word but I do
not know the exact terms... “(Researcher 2).
The quote by Researcher 2 captures a typical response
commonly given by researchers involved when asked
whether they had come across the concept of benefit
sharing.
On several occasions our respondents seemed una-
ware of the meaning of the term ‘benefit sharing’
although they insisted that they could infer the meaning
from its etymological roots as opposed to its usage in
ethics literature. In other cases, some researchers
reported that they had not come across the term ‘benefit
sharing’ as illustrated by the following excerpts of the
discussion between Researcher 7 and the interviewer.
Interviewer: Have you come across the term benefit
sharing before?
Response: Benefit sharing? No.
Interview: What do you think it is?
Response: That’s a hard ...., Benefit sharing... I guess
it’s both the participants benefitting from the study,
as the study benefits the clients, and the community,
probably... (Researcher 7)
Apart from the outright lack of awareness of the ethi-
cal concept, some researchers reported that they never
bothered with the finer details over issues relating to
benefit sharing but instead, operated on the assumption
that their institutions had taken necessary steps to oper-
ationalise it. The following quote by Researcher 15,
while indirectly illustrating some sense of awareness,
portrays a rather distanced engagement with the practi-
cal considerations relating to benefit sharing.
...what I know is that at the institute level, they are
coming up with the Intellectual Property Rights and Ben-
efit Sharing between the institute and the inventors. This
will take care of such issues and we don’t have to
worry....so the institute will also play its role as a place
to which we were affiliated and it will also have its bene-
fits (Researcher- 15).
In yet another instance, a researcher noted that there
was some unspoken assumption among researchers that
since research protocols are approved by respective
institutional review boards including Research Ethics
Committees (RECs) the issues concerning benefit shar-
ing had already been addressed, as illustrated by the fol-
lowing quote;
... Ok, since the research that we do, has to be
approved by the ethical review committee essentially
both the scientific committee and ethical review commit-
tee where we usually have to explain the sort of benefits
they are likely to get directly in the short term and also
you need to explain to them even the long term, how
they stand to benefit.... but most of the times we leave it
there... (Researcher3).
As expected, there were researchers, although clearly a
minority, who reported some awareness of the concept
as articulated in the quote by Researcher 13.
“...of course we have considered issues related to what
benefits come out of this research because it is an issue
that volunteers have been raising. However this has not
been explicitly addressed as has been other issues. When
we started these vaccine trials here, there was no frame-
work in the country to guide our operations...”
(Researcher13).
Research regulatory level: Awareness among members
of the IRBs
...the question of benefit sharing particularly in the
third world is a very tricky one. From a general point of
view the complaint has generally been that in collabora-
tive research in particular, the relationships say between
those in the third world and those in the first world has
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therefore works a lot of injustice. ...this makes pursuing
benefit sharing quite complex although in most of the
International forums where this has been discussed it is
clearly there... (Institutional Review Board 1).
Members of the Institutional review boards unlike
researchers showed some level of awareness of the con-
cept, although they were perplexed over the practical
implications over its consideration in research con-
ducted in Kenya. The above quote was a response to
how consideration for benefit sharing was handled
within protocols submitted by researchers. Similar chal-
lenges relating to lack of clarity over practicalities of
engaging with benefit sharing were further articulated
by members of different IRBs, who while responding to
a similar question observed that;.... It is very tricky. And,
I have been engaged in this debate (on benefit sharing)
myself and I have said yes, it is good but, let’sb ep r a c t i -
cal. Practically the implementation becomes impossible...
(Institutional Review Board 2). While these quotes by
members of IRBs illustrate concerns over feasibility of
engaging with benefit sharing in resource poor settings
they nonetheless show some degree of familiarity with
the concept. Although this degree of awareness is
expected among members of IRBs, their divergence in
opinion on the practicality of engaging with benefit
sharing in resource poor settings was striking, especially,
considering that both IRB 1 and IRB 2 were drawn from
the two main bodies with a final mandate for ethical
review of research protocols in Kenya.
Awareness at the community level: Awareness among
CSOs and other Community Representative Groups
...Benefit sharing is more or less taking ownership of what
comes out let’s say of an intervention or something like
that, like what you are saying like if we have to have col-
lective responsibility towards the fight against HIV and
Aids and out of that you find the prevalence rates are
going low, infections are quite reduced, there are few
infections or there is better life for those who are
infected...you see you also benefit, but we are also bene-
fiting as a large collective entity who put in collectively ...
(Civil Society Organisation 3).
Awareness of issues relating to benefit sharing at the
community level was explored by interviewing respon-
dents drawn from Civil Society Organisations (CSOs)s
and other community representative groups including
members of Community Advisory Boards (CABs) and
the KEMRI Community Representative (KCR) group.
The CSOs, CABs and the KCR were expected in theory
to champion community interests in research.
Another respondent from a CSO that was involved in
championing community interests within research
aimed at developing interventions to address malaria,
TB and HIV noted that;
....I think benefit sharing refer to a situation where all
t h ep a r t i e si n v o l v e di nag i v e ns i t u a t i o nf e e lp r o u df o r
the success that has been achieved, they feel part and
parcel of the mechanism and the system that has
brought about that success. So they feel more or less like
they have made life or the environment leaving it a bet-
ter place than it was initially...It is taking ownership of
the success. (Civil Society Organisation 5).
As was the case with other stakeholder groups there
were limited instances where respondents showed
awareness of issues relating to benefit sharing, as illu-
strated by the quote by Civil Society Organisation 2;
...Of course this is a subject, which has been recognized
and debated on the whole issue of benefit sharing, while
in the sense of clinical trials or in the sense of other
research whether its agricultural research, or biodiversity
research where you know at the end of the research there
is some kind of commercial product, I think it depends
on what is being looked at. In the area of clinical
research, the potential benefit from such work, in most
cases is pharmaceutical products, this could be a drug, it
could be a biological product, and it could even be a
medical device that is used in treatment, or could be a
v a c c i n eu s e di np r e v e n t i o n ,t h a t ’st h ep r o d u c t ... (Civil
Society Organisation 2).
In theory, this awareness, albeit limited, demonstrate
the extent to which some groups are able to discharge
their mandate of representing community interests
within global research enterprise. Broadly these
responses clearly show that there is little formal expo-
sure or joined up thinking with regard to the practical
aspects of interpreting abstract ethical guidance on the
ground.
Although respondents made only limited use of the
concept of benefit sharing as it is emerging in formal
ethical discourse, they nevertheless expressed a number
of views and concerns about health research that might
be considered to point towards the concept. We present
exemplars of these views below.
The scope for exploitation
“... There is disease, there is plenty of population, and
there is poverty..., there are plenty of poor people who
know nothing and who do not know their rights. So that
is why it is an easy field to come in and come out. Para-
chute in, Parachute out...they might be doing something
else also without you knowing. If they are drawing blood
samples, they’re telling you we are doing it for Malaria,
but do anybody have control over it, that those blood
samples are not going out and they are doing some
genetic testing or they are doing something else on it? /.../
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Board 5).
The quote is an acknowledgement that both indivi-
duals and communities participating in research were
vulnerable and therefore in need of protection. Such
explanations were given as the main reason for consid-
ering ethical issues in medical research. “...Ideally there
is need to ensure that researchers do not take advantage
of the subjects and... (ensure that)... whatever they are
doing is acceptable both ethically and scientifically”
(Researcher 4).
The potential for exploitation was further articulated
by reference to the common features that characterise
resource poor settings, including the huge unmet
healthcare needs, poverty and lack of a functional
research regulatory system, the above quote by
Researcher 4 captures some of the concerns among
members of the IRBs that health related research might
inadvertently promote unfairness among certain classes
of people in such settings. The metaphor of a parachute
appears to have been used here to illustrate the absence
of long-term relationship with the researched commu-
nity, either in understanding their needs (prior engage-
ment) or any thought about the impacts of research. It
is however important to note that there are situations in
which long-term relationships between research insti-
tutes and communities have been established and this
perhaps generates different obligations. The remarks
above were made in reference to the concern over vul-
nerability, and the attendant need for protection against
exploitation as previously noted. While these quotes
broadly speaks about the need to protect communities
from exploitation, it goes beyond the vulnerability pro-
duced by conditions of poverty, to also address the
potential for local researchers to involve communities in
research that is scientifically and ethically sound, but
still lacking value to such communities. Where there are
conditions of poverty, limited knowledge and the
absence of strong mechanisms to govern and regulate
research activities, consideration for benefit sharing is
seen as being capable of establishing standards to avert
crises that are likely to arise from participation in global
health research by local communities.
Addressing immediate health care and other societal
needs
“...I’d say that the people here come against economic
difficulties, that if one involves himself in that research,
he expects to be taken care of in terms of access to
health/.../for instance, if a child is ill and needs to go to
hospital they will get help from the research team...”
(Kemri Community Representative 5).
The second concern relates to the need to use
resources associated with research in addressing the
material conditions of communities that host/participate
in research as illustrated by the above quote by a mem-
ber of a community representative group.
Similar concerns were echoed by some locally based
researchers who reported that while the provision of
health care services is not the primary goal of research,
the dichotomy between research and other social issues
should not be stringently applied in poor settings where
people have high unmet health care needs.
“...I know it’s still like the Governments’ thing to do
some of those things, but...you should not say I think this
is for research, when another person is dying and you
have the medicines, I think it’s not fair. Even if you have
the equipment for research, it can be used for diagnostics
if it’s so needed.” (Researcher 2).
From this appeal to expectations which are brought
into the research process by research participants and
the call to disregard the dichotomy between research
and health care provision, it appears that some of these
stakeholders expect the resources associated with
research, to be used for responding to the needs of the
community, including those related to health care.
Future needs: the importance of access to future
interventions and treatments
“... we are learning and we have learnt something from
previous research, we have to act now by looking ahead
of the vaccine trials as opposed to waiting until the end
of the trials and ask ourselves, what will happen in
future and start asking those questions ourselves; how
will Kenya benefit? How will those individuals benefit? If
we can answer those questions now it will be so nice and
save us a lot of problems” (Civil Society Organisation 1).
Apart from responding to immediate health care
needs, some respondents saw opportunities from partici-
pation in health research as potentially securing future
access to proven interventions once research was com-
plete. The emphasis on learning and the time dimension
for planning were made in reference to HIV/AIDs vac-
cine trials that were previously undertaken in Kenya but
later culminated in disputes over ownership of the
results and the expected products pitting the collaborat-
ing institutions on one hand, and the research partici-
pants on the other.
“... It was not an easy fight to get the pharmaceutical
companies to see this point of view to recognize the glo-
bal corporate social responsibility, to sensitize them to
the need and of course there are a lot of people who are
suffering from these diseases in the developing world,
who are unable to access these drugs because they can-
not afford it...” (Civil Society Organisation 2).
The importance of forward thinking as a way of pro-
moting future access of research benefits was equally
underscored by reflecting on previous struggles between
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tries. By making reference to previous drug trials con-
ducted in resource poor settings, which led to the
development of effective antiretroviral therapies (ARTs),
the quote by Civil Society Organisation 2 demonstrates
the potential of benefit sharing to address future com-
munity needs relating to proven interventions.
Research and sharing profits
“...I think its business, in my view. Lately I’ve come to
understand that research especially big time research out
there is a huge industry. And people will put money on
what they see as potentially giving back to them in the
future...” (Institutional Review Board 3).
Other respondents regarded consideration for benefit
sharing as a tool to foster recognition of the huge
opportunities for investment presented by research and
the need to enjoin all stakeholders in reaping the bene-
fits. The quote by Institutional Review Board 3a b o v e
for instance, represents a concern expressed by local
level stakeholders (including members of community
advisory boards, community representative groups,
researchers and the IRBs) to liken health related
research to a business venture whose goal is the pursuit
of profit.
The stakeholder accounts presented above therefore
underscore the importance of fairness especially in the
context of recognising contribution made by research
participants and their communities, by participating in
the development of medical and public health tools
through research.
Developing community support
“... What is the benefit of this for us? You will realise
that for the last almost 12 years and especially in the
previous decade (the industry) was seen to just purely
profit from human suffering and people had a very nega-
tive view of the Pharmaceutical Industry. And in the last
10 years, we are sort of re-modelling our self and trying
to make sure we project our self in a very responsible
manner...” (Pharmaceutical company1)
On the other hand, some stakeholders especially those
associated with the funding of health research appealed
to the importance of cultivating community support and
goodwill by responding to the previous negative press
that characterised the conduct of collaborative research
in resource poor settings as aptly summarised by the
above quote by Pharmaceutical company1.
Resource and risk pooling
“... So our R&D people are coming from the Industry, so
we understand it. The multinational big Pharmaceuti-
cals, if they want to do something there because they see
the need, they also see the urge from the Global
Community, they want to limit their financial exposure
in the R&D at least part of the cost are borne by some-
one else, by the Public Community and also far as the
risk, if one Project fails then maybe there will be other
Projects coming afterwards” (Public Private Partnership
2).
A related benefit for considering benefit sharing was
the need to develop a collective approach to enlisting
community support by pooling together resources that
can be invested in the development of medical and
public health research whose return on investment
( R O I )w a sn o tg u a r a n t e e da ss u m m a r i s e db yP u b l i c
Private Partnership 2 above. This particular quote a
voice of a stakeholder from a public private partner-
ship, commenting on how appeals to collective
resource pooling between the public and private enter-
prises had successfully been used to address challenges
associated with the funding of research into “neglected
diseases”. Prior to the establishment of partnerships
between the public and private ventures, pharmaceuti-
cal industries mainly relied on a pure business logic/
model in making decisions to invest in the develop-
ment of health interventions. Such investment deci-
sions were the subject of debate and criticisms,
following the publication of the 10/90 report (the sta-
tistical finding by the Global Forum for Health
Research, that only ten per cent of the world expendi-
ture on health research and development was devoted
to the health problems that primarily affect the poorest
90 per cent of the world’s population) on Health
Research by the Global Forum for Health Research. In
response, the pharmaceutical industry teamed with
other players to develop alternative funding mechan-
isms to facilitate research into diseases of public health
importance to resource poor settings.
Making actors accountable/socially responsible
In addition, there were concerns touching on account-
ability among actors involved in research as illustrated
by the quote by Institutional Review Board 5.
“... I think you should be realistic, that nobody is going
to come back and you may not be there to enforce that
somebody should give back to the community...and once
they find what they are looking for, they may just take
off...” (Institutional Review Board 5).
The concern over whether research sponsors are likely
to be accountable to the host community especially in
the absence of strong governance and regulatory
mechanisms was a key consideration among IRBs and
other local level stakeholders. More importantly, the
quote underscores the underlying fear that some actors
might take advantage of weaknesses within these regula-
tory mechanisms, and exploit local communities by fail-
ing to make research benefits available.
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In this study we aimed first; to explore the understand-
ing of the concept of benefit sharing among stake-
holders involved in health related research in Kenya and
second, to examine the extent to which this understand-
ing had resulted in practical steps to protect the inter-
ests of individuals and communities who participate in
health related research in Kenya. In order to achieve
this, interviews were conducted with stakeholders that
often influence the ethical conduct of health research in
the country.
One of the anticipated outcomes was that stakeholders
would show awareness [24]of the debates relating to
benefit sharing and the promotion of the social value of
research, and the internal logic for engaging with benefit
sharing within global health research. What our findings
however show is that in most cases, there is a very lim-
ited formal engagement with recent mainstream think-
ing over the need to promote justice and equity in
global health research.
Clearly, there has been significant debate at the inter-
national level over the last decade, regarding the ethics
of global health, including promulgation of various
research ethics guidelines [25]. Despite this, it appears
that most stakeholders key among them researchers,
IRBs, policy makers, regulatory bodies and CSOs have
largely been passive recipients of these ethical recom-
mendations. The apparent disconnect between research-
ers and IRBs is for instance quite revealing, because
IRBs are in theory expected to provide guidance to
researchers in operationalising ethical requirements in
practice. Both researchers and IRBs are expected to play
a key role in promoting ethical conduct of health related
research involving human subjects.
Our findings further suggest that despite this limited
engagement with the formal thinking within global
health research, stakeholders have a number of key
moral concerns associated with participation of poor
communities in international research. These concerns
included a sense of the need to ensure fairness in the
distribution of benefits arising from research. Demands
for fairness might be attributed to several other factors,
including some that are political in nature, but there
was also a growing sense in which health related
research was regarded as a joint activity not only invol-
ving researchers and sponsors, but also other players
including the host communities. Such perceptions
seemed to be based on a belief that research involves
the active participation of communities and participants
as something like ‘co-producers’, where the actors
involved in whatever capacity are entitled to a stake in
the proceeds derived from research. The metaphor of
co-producing is important, in the sense that facilitating
research either by giving information or body tissue is
in itself seen as a form of capital, and as is the case in
any act of production, contribution must be rewarded
accordingly, which potentially pushes participation in
research away from volunteerism. Interestingly, claims
over co-production are not confined to types of research
that are aimed at producing commercial products, but
were also common in other types of research such as
epidemiology and health systems research. Similar
notions of members of the collective as co-producers
have been described elsewhere [5,26]. Promoting fair-
ness in the distribution of proceeds from research has
for instance played a critical role in pushing for recogni-
tion of the interests of different actors involved in
research and bringing them to the negotiating table [5].
Other concerns that were voiced relate to demands for
some of resources tied to health research, and particu-
larly international collaborative research, to be chan-
nelled to addressing unmet health care needs of the
local community [3,27,28], and the need to protect poor
communities against exploitation. Lastly, by talking
about the importance of putting in place strong and
binding mechanisms that ensure that agreements made
during the negotiation are honoured, these actors were
perhaps pointing to the lack of accountability and trust
in the manner in which research had previously been
conducted.
Whilst respondents made many observations indicat-
ing the importance of benefits to individuals and com-
munities of those participating in health research, their
comments also showed that practical implementation of
benefit sharing would be complex, contentious and diffi-
cult to achieve.
These findings have several practical implications for
global health research in general, and engaging commu-
nities in research, especially in the context of collabora-
tive health related research in resource poor settings.
Firstly, they demonstrate the fact that while in theory
several efforts can be made to address the moral issues of
concern to research participants and their communities
in resource poor settings, careful thought should be given
on the practical aspects of implementing strategies such
as benefit sharing. Secondly, the findings point to an
urgent need to pay particular attention to the processes
through which communities and other stakeholders are
recruited into biomedical research as a starting point
towards developing better strategies of promoting partici-
pation and engagement in global health research. Thirdly,
they demonstrate that while rapid theoretical leaps can
be made in promoting the ethics of global health
research, progress in real life will always be incremental.
Sadly, opportunities for documenting and learning from
these incremental steps are currently missing.
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Developing a clear, feasible and shared approach to ben-
efit sharing from health research is a long way from a
reality in the Kenyan context. In particular, in this
study, we have shown that various categories of stake-
holders involved in health research in Kenya have a
rather limited view of the moral and ethical debates that
preceded consideration for benefit sharing and social
value as ethical imperatives within global health
research.
There is some limited receptivity among stakeholders,
to ethical reflection regarding the conduct of health
research in these settings. However, this receptivity has
not necessarily led to recognition or internalisation of
globally discussed principles. Closer attention to the
processes through which ethical principles are enacted
in practice is needed, including distilling lessons on how
best to involve individuals and communities in promot-
ing ethical conduct of global health research in resource
poor settings.
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